3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
63
Carcinoma, Hepatocellular
55
Lung Neoplasms
32
Breast Neoplasms
29
Small Cell Lung Carcinoma
23
Neoplasms
21
Triple Negative Breast Neoplasms
18
Neoplasm Metastasis
17
Urinary Bladder Neoplasms
15
Carcinoma, Transitional Cell
15
Melanoma
14
Colorectal Neoplasms
14
Glioblastoma
10
Prostatic Neoplasms
9
Ovarian Neoplasms
9
Head and Neck Neoplasms
9
Recurrence
8
Liver Neoplasms
8
Endometrial Neoplasms
8
Carcinoma, Renal Cell
8
Mesothelioma, Malignant
7
Uterine Cervical Neoplasms
6
Sarcoma
6
Stomach Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Rectal Neoplasms
5
Kidney Neoplasms
5
Gastrointestinal Neoplasms
5
Carcinoma, Squamous Cell
5
Pancreatic Neoplasms
4
Interventions
pembrolizumab
4
Nivolumab
3
toripalimab
2
sintilimab
2
Neoadjuvant Therapy
2
Celecoxib
2
tislelizumab
1
spartalizumab
1
relatlimab
1
regorafenib
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
denileukin diftitox
1
danvatirsen
1
camrelizumab
1
avelumab
1
atezolizumab
1
XELOX
1
Taxes
1
Surgical Procedures, Operative
1
Radiation Dose Hypofractionation
1
Paclitaxel
1
Megestrol Acetate
1
Medroxyprogesterone Acetate
1
Ipilimumab
1
Induction Chemotherapy
1
Immunotherapy
1
Immunoglobulin G
1
Immune Checkpoint Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Turcot syndrome
×
atezolizumab
×
Clear all
NCT05118724
2025-06-15
ANTONIO
AIO-Studien-gGmbH
Phase 2
Active not recruiting
80 enrolled